MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited Market Cap 2011-2026 | VNRX
As of March 24, 2026 VolitionRx Limited has a market cap of $ 20.2 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.8 M | 58.1 M | 89.1 M | 157 M | 200 M | 185 M | 79.7 M | 92.6 M | 107 M | 66.8 M | 67.2 M | 27.1 M | 23.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 200 M | 23.4 M | 92.9 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Interpace Biosciences
IDXG
|
4.12 M | $ 1.71 | 0.73 % | $ 7.5 M |  USA |
 |
Illumina
ILMN
|
16.4 B | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.13 | -2.74 % | $ 4.89 M | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
NeoGenomics
NEO
|
1.48 B | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | $ 104.91 | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
315 M | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
5.31 B | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
34.9 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
OPKO Health
OPK
|
1.21 B | $ 1.15 | 2.68 % | $ 798 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Personalis
PSNL
|
254 M | $ 7.61 | 4.82 % | $ 451 M | USA |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
28.3 B | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
IDEXX Laboratories
IDXX
|
51.1 B | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
3.55 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Senseonics Holdings
SENS
|
351 M | $ 6.62 | 2.16 % | $ 276 M | USA |
 |
Sotera Health Company
SHC
|
4.75 B | $ 13.88 | 2.81 % | $ 3.94 B | USA |
 |
Agilent Technologies
A
|
42 B | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
2.08 B | $ 31.72 | -4.52 % | $ 1.61 B | USA |
 |
DarioHealth Corp.
DRIO
|
32.8 M | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
13.4 B | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
Myriad Genetics
MYGN
|
409 M | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
Psychemedics Corporation
PMD
|
16.8 M | - | -1.84 % | $ 15.3 M | USA |
 |
Neuronetics
STIM
|
81.1 M | $ 1.6 | 10.34 % | $ 106 M | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
CareDx, Inc
CDNA
|
993 M | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
ENDRA Life Sciences
NDRA
|
2.2 M | $ 3.48 | 0.87 % | $ 1.87 M | USA |
 |
Thermo Fisher Scientific
TMO
|
196 B | $ 478.12 | 0.79 % | $ 180 B | USA |
 |
Celcuity
CELC
|
399 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 264.42 | 0.54 % | $ 22 B | USA |